Related Experiment Videos
Dynamic hepatic scintigraphy in colorectal cancer
D M Hemingway1, T G Cooke, H Warren
1University Department of Surgery, Royal Infirmary, Glasgow, UK.
Nuclear Medicine Communications
|October 1, 1995
Summary
The hepatic perfusion index (HPI) is often elevated in patients with colorectal cancer and liver metastases. This finding may help in diagnosing liver involvement early in cancer patients.
Area of Science:
- Oncology
- Radiology
- Hepatology
Background:
- Colorectal cancer (CRC) is a significant global health concern.
- Early detection of liver metastases in CRC is crucial for patient outcomes.
- The hepatic perfusion index (HPI) is a radiological measurement.
Purpose of the Study:
- To evaluate the clinical utility of the hepatic perfusion index (HPI) at presentation for patients with colorectal cancer.
- To determine if an elevated HPI correlates with the presence of hepatic metastases.
Main Methods:
- A study was conducted on 83 consecutive patients diagnosed with colorectal cancer.
- The hepatic perfusion index (HPI) was measured at the time of presentation.
- Patients were assessed for the presence of overt liver metastases.
Main Results:
- An abnormally elevated HPI was observed in 34 out of 37 patients (93%) with overt liver metastases.
- The study confirmed a high correlation between elevated HPI and the presence of hepatic metastases in colorectal cancer patients.
Conclusions:
- The hepatic perfusion index (HPI) is elevated in the majority of colorectal cancer patients with overt liver metastases.
- Further long-term follow-up is ongoing for patients with an abnormal HPI but no initially obvious liver metastases.